HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE COVER ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Submit a letter to the editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bonadonna, G. Articles by Salvadori, B. Search for Related Content PubMed PubMed Citation Articles by Bonadonna, G. Articles by Salvadori, B.

CA: A Cancer Journal for Clinicians, Vol 45, Issue 4 227-243, Copyright © 1995 by American Cancer Society

ARTICLES

Primary chemotherapy in surgically resectable breast cancer

G. Bonadonna, P. Valagussa, R. Zucali and B. Salvadori
Division of Medical Oncology, Istituto Nazionale Tumori in Milan, Italy.

We have reviewed the current status of primary chemotherapy for resectable breast cancer in view of the possibility that it may improve on results of present adjuvant drug therapies. The observed kinetic acceleration of micrometastases following noncurative surgical excision in animal studies represents strong biologic evidence supporting primary chemotherapy. From a clinical perspective, primary chemotherapy has consistently reduced the frequency of mastectomy in women with tumors initially considered too large for breast-conserving surgery. From studies of various drug combinations, it appears that the incidence of pathologic complete remission usually remains less than 10 percent. Based on results from the Milan study, it appears that the degree of tumor response is a marker of treatment outcome, at least for the first five years. A higher complete-remission rate could be expected by combining doxorubicin with paclitaxel, as has already been observed in the treatment of clinically disseminated breast cancer. In spite of the logical and scientific rationale, the available data do not as yet provide sufficient evidence to indicate a clear superiority of primary chemotherapy over adjuvant chemotherapy. The real question to answer through prospective, randomized trials is not whether the shift from adjuvant to neoadjuvant chemotherapy will result in a superior outcome, but rather how to properly integrate effective primary and adjuvant drug regimens to maximize tumor cell kill. This strategy should be further tested in patients at high risk for occult axillary adenopathy and/or distant micrometastases (i.e., tumor size larger than 2 to 3 cm). However, a more-refined risk assessment approach (e.g., using tumor grade or proliferative index) will clearly be needed. The new treatment approach may also allow for a wider use of fine-needle aspiration biopsy to obtain the primary diagnosis of cancer, a more uniform adoption of breast-conserving surgery, and use of response to chemotherapy as a marker of treatment outcome.

This article has been cited by other articles:

				F. Peintinger, H. M. Kuerer, K. Anderson, J. C. Boughey, F. Meric-Bernstam, S. E. Singletary, K. K. Hunt, G. J. Whitman, T. Stephens, A. U. Buzdar, et al. Accuracy of the Combination of Mammography and Sonography in Predicting Tumor Response in Breast Cancer Patients After Neoadjuvant Chemotherapy Ann. Surg. Oncol., November 1, 2006; 13(11): 1443 - 1449. [Abstract] [Full Text] [PDF]

				T.R. J. Evans, A. Yellowlees, E. Foster, H. Earl, D. A. Cameron, A. W. Hutcheon, R. E. Coleman, T. Perren, C. J. Gallagher, M. Quigley, et al. Phase III Randomized Trial of Doxorubicin and Docetaxel Versus Doxorubicin and Cyclophosphamide As Primary Medical Therapy in Women With Breast Cancer: An Anglo-Celtic Cooperative Oncology Group Study J. Clin. Oncol., May 1, 2005; 23(13): 2988 - 2995. [Abstract] [Full Text] [PDF]

				V. Dieras, P. Fumoleau, G. Romieu, M. Tubiana-Hulin, M. Namer, L. Mauriac, J.-P. Guastalla, E. Pujade-Lauraine, P. Kerbrat, P. Maillart, et al. Randomized Parallel Study of Doxorubicin Plus Paclitaxel and Doxorubicin Plus Cyclophosphamide As Neoadjuvant Treatment of Patients With Breast Cancer J. Clin. Oncol., December 15, 2004; 22(24): 4958 - 4965. [Abstract] [Full Text] [PDF]

				I. C. Smith, S. D. Heys, A. W. Hutcheon, I. D. Miller, S. Payne, F. J. Gilbert, A. K. Ah-See, O. Eremin, L. G. Walker, T. K. Sarkar, et al. Neoadjuvant Chemotherapy in Breast Cancer: Significantly Enhanced Response With Docetaxel J. Clin. Oncol., March 15, 2002; 20(6): 1456 - 1466. [Abstract] [Full Text] [PDF]

				J. Abrahamova, M. Wagnerova, E. Kubala, V. Malec, E. Simova, I. Sirakova, E. Pavlikova, D. Machova, I. Kocak, I. Pavlikova, et al. Vinorelbine, Epirubicin, and Methotrexate (VEM) as Primary Treatment in Locally Advanced Breast Cancer Oncologist, August 1, 2001; 6(4): 347 - 352. [Abstract] [Full Text] [PDF]

				I. C. Smith, A. E. Welch, A. W. Hutcheon, I. D. Miller, S. Payne, F. Chilcott, S. Waikar, T. Whitaker, A. K. Ah-See, O. Eremin, et al. Positron Emission Tomography Using [18F]-Fluorodeoxy-D-Glucose to Predict the Pathologic Response of Breast Cancer to Primary Chemotherapy J. Clin. Oncol., April 1, 2000; 18(8): 1676 - 1688. [Abstract] [Full Text] [PDF]

				M. Schelling, N. Avril, J. Nahrig, W. Kuhn, W. Romer, D. Sattler, M. Werner, J. Dose, F. Janicke, H. Graeff, et al. Positron Emission Tomography Using [18F]Fluorodeoxyglucose for Monitoring Primary Chemotherapy in Breast Cancer J. Clin. Oncol., April 1, 2000; 18(8): 1689 - 1695. [Abstract] [Full Text] [PDF]

				J. F. Eary, D. A. Mankoff, L. K. Dunnwald, D. R. Byrd, B. O. Anderson, R. S. Yeung, and R. E. Moe Sentinel Lymph Node Mapping for Breast Cancer: Analysis in a Diverse Patient Group Radiology, October 1, 1999; 213(2): 526 - 529. [Abstract] [Full Text]

				B. Thurlimann and H.-J. Senn The Changing Approach to the Treatment of Early Breast Cancer N. Engl. J. Med., May 23, 1996; 334(21): 1397 - 1399. [Full Text]